Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L5FB
|
||||
| Former ID |
DNCL002924
|
||||
| Drug Name |
TAK-329
|
||||
| Indication | Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] | Phase 1 | [523386] | ||
| Company |
Takeda Pharmaceuticals U.S.A.
|
||||
| Target and Pathway | |||||
| Target(s) | Glucokinase | Target Info | Inhibitor | [551984] | |
| KEGG Pathway | Glycolysis / Gluconeogenesis | ||||
| Galactose metabolism | |||||
| Starch and sucrose metabolism | |||||
| Amino sugar and nucleotide sugar metabolism | |||||
| Butirosin and neomycin biosynthesis | |||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Carbon metabolism | |||||
| Insulin signaling pathway | |||||
| Insulin secretion | |||||
| Prolactin signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Maturity onset diabetes of the young | |||||
| Central carbon metabolism in cancer | |||||
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | ||||
| HIF-1-alpha transcription factor network | |||||
| References | |||||